Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma

Inclusion Criteria: * Tissue diagnosis of lymphoplasmacytic lymphoma with surface immunoglobulin G (IgG), immunoglobulin A (IgA) or immunoglobulin M (IgM) phenotype with a monoclonal heavy and light chain as determined by flow cytometry; all primary diagnostic lymph node and/or bone marrow biopsies will be reviewed at the University of Texas M.D. Anderson Cancer Center (UTMDACC) * Previously untreated patients with lymphoplasmacytic lymphoma (of any subtype: IgG, IgA, IgM) in the asymptomatic phase * Patients must provide a lymph node sample of at least 1.5 cm in the long axis, or a bone marrow aspiration sample providing at least 5 million cluster of differentiation (CD)20 and/or CD38+ (approximately 10 ml) * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Serum creatinine =\< 1.5 mg/dl and a creatinine clearance \>= 30 ml/min * Total bilirubin =\< 1.5 mg/dl unless felt secondary to Gilbert's disease * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 2 x upper limit of normal * Ability to provide informed consent, and to return to clinic for adequate follow-up for the period that the protocol requires * Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and for 30 days after the last vaccination has been administered * Male subject agrees to use an acceptable method for contraception for the duration of the study Exclusion Criteria: * Human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C infection * Pregnancy or lactating females * Patients with previous history of malignancy within the last 5 years except curatively treated squamous or basal cell carcinoma of the skin or curatively treated carcinoma in-situ of other organs * Any medical or psychiatric condition that in the opinion of the principal investigator would compromise the patient's ability to tolerate this treatment * Patients with New York Heart Association class 3 or 4 disease * Patients with a history of autoimmune diseases except for Hashimoto's thyroiditis * Patients with positive antinuclear antibody (ANA) and/or anti-double strand (ds) DNA antibodies